Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;77(7):733-745.
doi: 10.1007/s40265-017-0733-1.

The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies

Roy Lirov  1   2 , Francis P Worden  3 , Mark S Cohen  4   5
Affiliations

The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies

Roy Lirov et al. Drugs. 2017 May.

Abstract

Until recently, patients with advanced thyroid cancers had limited options for systemic treatment. With the introduction of tyrosine kinase inhibitors (TKIs) as a promising new class of targeted therapies for thyroid cancer, suddenly patients with advanced disease were given new options to extend survival. Guidelines worldwide have been updated to include general indications for these newer agents, but questions remain regarding which agent(s) to select, when to begin treatment, and how long therapy should continue. Additionally, the true impact of TKIs on overall survival and quality-of-life in thyroid cancer patients needs further clarification. As familiarity with approved agents and longer-term data become available, better strategies for implementation of these targeted drugs will evolve to optimize benefit for patients living with metastatic disease.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Systemic Therapy Decision-Making Matrix
Figure 2
Figure 2
First-line Treatment Algorithm for Disseminated Metastasis
Figure 3
Figure 3
Algorithm for Disease Progression on TKI *Or clinical trial
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER Cancer Statistics Review, 1975–2013. National Cancer Institute; Bethesda, MD,: Apr, 2016. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site.
    1. National Comprehensive Cancer Network (NCCN) [Accessed 8/1/2016];Clinical Practice Guidelines in Oncology, Thyroid Carcinoma. 2016 Available From: https://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf.
    1. Aschebrook-kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 2011;21(2):125–34. - PMC - PubMed
    1. Haddad RI, Lydiatt WM, Ball DW, et al. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015;13(9):1140–50. - PMC - PubMed

MeSH terms

Substances